source
- Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trialRegeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
- Chinese biotech CEOs target creation of up to ten global Big Pharma firms within a decadeChinese drug developers have shifted from generic manufacturing to aiming for a seat at the global Big Pharma table, according to recent interviews. The country now ranks second after the United S…